BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31473880)

  • 1. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
    Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
    J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m
    Benavides-Serrato A; Saunders JT; Kumar S; Holmes B; Benavides KE; Bashir MT; Nishimura RN; Gera J
    Cancer Lett; 2023 May; 562():216178. PubMed ID: 37061119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
    Holmes B; Lee J; Landon KA; Benavides-Serrato A; Bashir T; Jung ME; Lichtenstein A; Gera J
    J Biol Chem; 2016 Jul; 291(27):14146-14159. PubMed ID: 27226604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.
    Benavides-Serrato A; Saunders JT; Holmes B; Nishimura RN; Lichtenstein A; Gera J
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1.
    Gao G; Dhar S; Bedford MT
    Nucleic Acids Res; 2017 May; 45(8):4359-4369. PubMed ID: 28115626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.
    Martin J; Masri J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Anderson L; Bashir T; Bernath A; Lichtenstein A; Gera J
    J Biol Chem; 2011 May; 286(18):16402-13. PubMed ID: 21454539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.
    Jo OD; Martin J; Bernath A; Masri J; Lichtenstein A; Gera J
    J Biol Chem; 2008 Aug; 283(34):23274-87. PubMed ID: 18562319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
    Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
    Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-translational modifications of hnRNP A1 differentially modulate retroviral IRES-mediated translation initiation.
    Barrera A; Ramos H; Vera-Otarola J; Fernández-García L; Angulo J; Olguín V; Pino K; Mouland AJ; López-Lastra M
    Nucleic Acids Res; 2020 Oct; 48(18):10479-10499. PubMed ID: 32960212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRMT5 as a druggable target for glioblastoma therapy.
    Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
    Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
    Zhang S; Ma Y; Hu X; Zheng Y; Chen X
    J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective PRMT5 Inhibitors Suppress Human CD8
    Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
    Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
    Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
    Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.
    Cloninger C; Bernath A; Bashir T; Holmes B; Artinian N; Ruegg T; Anderson L; Masri J; Lichtenstein A; Gera J
    Mol Cancer Ther; 2011 Dec; 10(12):2244-56. PubMed ID: 21911485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
    Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
    J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.
    Shi Y; Sharma A; Wu H; Lichtenstein A; Gera J
    J Biol Chem; 2005 Mar; 280(12):10964-73. PubMed ID: 15634685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
    Mongiardi MP; Savino M; Bartoli L; Beji S; Nanni S; Scagnoli F; Falchetti ML; Favia A; Farsetti A; Levi A; Nasi S; Illi B
    Sci Rep; 2015 Nov; 5():15494. PubMed ID: 26563484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.